The strong efficacy and safety data for CRB-701 in multiple cancer indications suggests significant commercial potential, particularly in HNSCC and cervical cancer where it outperforms current treatments. The obesity data for CRB-913 is early but shows a potentially best-in-class profile with rapid weight loss and excellent tolerability.
Price Chart
Executive Summary
Corbus Pharmaceuticals updated its corporate presentation with positive clinical data from its pipeline. CRB-701 showed strong efficacy in head and neck and cervical cancers with a favorable safety profile compared to competitors. CRB-913 demonstrated promising early weight loss results in obesity with minimal side effects. The company has $173M in cash and key catalysts expected in 2026.
Key Facts
- CRB-701 showed 47.6% ORR in HNSCC and 37.5% ORR in cervical cancer
- CRB-701 has significantly better safety profile than competitors with only 8.4% peripheral neuropathy vs 48% for PADCEV
- CRB-913 showed 2.9% placebo-adjusted weight loss in 14 days with no GI side effects
- Company has $173M cash as of November 2025 with ~17.6M shares outstanding
- Key 2026 catalysts include Phase 1b CRB-913 data, CRB-701 registrational studies, and combination data with pembrolizumab
Financial Impact
$173M cash position with no immediate dilution risk
Risk Factors
- Clinical data is from early trials and may not be replicated in larger studies
- Competitive landscape in both oncology and obesity is intense with established players
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (CRBP) — Batch item 1 | 0001193125-26-068566 |
| Document: crbp-20260225.htm | 0001193125-26-068566 |
| Document: 0001193125-26-068566-index-headers.html | 0001193125-26-068566 |
| Document: 0001193125-26-068566-index.html | 0001193125-26-068566 |
| Document: 0001193125-26-068566.txt | 0001193125-26-068566 |
| 8-K Filing (CRBP) — Batch item 6 | 0001193125-26-068566 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $4.33 | awaiting T+60 | — | $3.99 (−7.85%) |
Sep 30, 2026 27d ago | SC 13G | $6.34 | awaiting T+60 | — | $3.99 (−37.07%) |
Sep 22, 2026 5w ago | Institutional Cluster | $7.88 | awaiting T+60 | — | $3.99 (−49.33%) |
Sep 14, 2026 6w ago | 8-K | $8.08 | awaiting T+60 | — | $3.99 (−50.62%) |
Sep 11, 2026 6w ago | Press Release | $8.08 | awaiting T+60 | — | $3.99 (−50.62%) |
Aug 12, 2026 10w ago | Insider Cluster | $10.08 | awaiting T+60 | — | $3.99 (−60.42%) |
Aug 10, 2026 11w ago | Insider Cluster | $9.51 | awaiting T+60 | — | $3.99 (−58.04%) |
May 26, 2026 22w ago | 8-K | $7.91 $9.99 | ▲ +26.30% | ▲ +23.57% | $3.99 (−49.56%) |
May 21, 2026 22w ago | 8-K | $11.51 $10.49 | ▼ −8.86% | ▼ −13.16% | $3.99 (−65.33%) |
May 14, 2026 23w ago | 8-K | $11.98 $9.46 | ▼ −21.04% | ▼ −24.62% | $3.99 (−66.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers